Search: onr:"swepub:oai:DiVA.org:uu-343107" >
A randomized, doubl...
A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease.
-
Marrinan, Sarah L (author)
-
Otiker, Tal (author)
-
Vasist, Lakshmi S (author)
-
show more...
-
Gibson, Rachel A (author)
-
Sarai, Bhopinder K (author)
-
Barton, Matthew E (author)
-
Richards, Duncan B (author)
-
- Hellström, Per M., 1954- (author)
- Uppsala universitet,Gastroenterologi/hepatologi
-
- Nyholm, Dag (author)
- Uppsala universitet,Neurologi
-
Dukes, George E (author)
-
Burn, David J (author)
-
show less...
-
(creator_code:org_t)
- 2017-12-26
- 2018
- English.
-
In: Movement Disorders. - : Wiley. - 0885-3185 .- 1531-8257. ; 33:2, s. 329-332
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://onlinelibrar...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BACKGROUND: Delayed gastric emptying may impair l-dopa absorption, contributing to motor fluctuations. We evaluated the effect of camicinal (GSK962040), a gastroprokinetic, on the absorption of l-dopa and symptoms of PD.METHODS: Phase II, double-blind, placebo-controlled trial. Participants were randomized to receive camicinal 50 mg once-daily (n = 38) or placebo (n = 20) for 7 to 9 days.RESULTS: l-dopa exposure was similar with coadministration of camicinal compared to placebo. Median time to maximum l-dopa concentration was reduced, indicating more rapid absorption of l-dopa. Camicinal resulted in significant reduction in OFF time (-2.31 hours; 95% confidence interval: -3.71, -0.90), significant increase in ON time (+1.88 hours; 95% confidence interval: 0.28, 3.48) per day, and significant decrease in mean total MDS-UPDRS score (-12.5; 95% confidence interval: -19.67, -5.29). Camicinal treatment was generally well tolerated.CONCLUSIONS: PD symptom improvement with camicinal occurred in parallel with more rapid absorption of l-dopa. This study provides evidence of an improvement of the motor response to l-dopa in people with PD treated with camicinal 50 mg once-daily compared with placebo, which will require further evaluation.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- Clinical trials Randomized controlled (CONSORT agreement)
- Parkinson's disease/parkinsonism
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Marrinan, Sarah ...
-
Otiker, Tal
-
Vasist, Lakshmi ...
-
Gibson, Rachel A
-
Sarai, Bhopinder ...
-
Barton, Matthew ...
-
show more...
-
Richards, Duncan ...
-
Hellström, Per M ...
-
Nyholm, Dag
-
Dukes, George E
-
Burn, David J
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Neurology
- Articles in the publication
-
Movement Disorde ...
- By the university
-
Uppsala University